Description
Tazodim 1.125 g Injection is a potent antibacterial combination of Ceftazidime (third-generation cephalosporin) and Tazobactam (β-lactamase inhibitor). This formulation is specifically designed to provide enhanced activity against resistant Gram-negative organisms, including difficult-to-treat hospital-acquired infections.
Composition (Typical)
- Ceftazidime IP – 1000 mg
- Tazobactam Sodium IP – 125 mg
- Total: 1.125 g
Mechanism of Action
- Ceftazidime: Inhibits bacterial cell wall synthesis, leading to bactericidal activity
- Tazobactam: Protects Ceftazidime from β-lactamase degradation, extending its spectrum against resistant pathogens
Indications
- Hospital-acquired and ventilator-associated pneumonia
- Complicated urinary tract infections (cUTIs)
- Intra-abdominal infections
- Septicemia
- Skin & soft tissue infections
- Bone & joint infections
Dosage & Administration
- Administer via Intramuscular (IM) or Intravenous (IV) route
- Reconstitute with appropriate diluent before administration
- Dosage to be determined by the physician based on infection severity
Key Benefits
- Strong activity against Gram-negative pathogens including Pseudomonas aeruginosa
- Enhanced efficacy with β-lactamase inhibitor (Tazobactam)
- Ideal for serious and resistant infections
- Suitable for ICU and hospital settings
Precautions
- Use cautiously in patients with cephalosporin allergy
- Dose adjustment required in renal impairment
- Monitor for superinfection with prolonged use
Storage
- Store below 25°C
- Protect from light
- Use immediately after reconstitution
Pack Details
- Vial containing 1.125 g dry powder for injection
